FDA批准乙肝注射药物Hibsago,允许部分患者停止所有治疗
FDA approves hepatitis B shot that may let some patients stop all treatment
美国FDA批准Hibsago(bepirovirsen)用于特定慢性乙肝成人患者,成为该类首个获批药物。该疗法允许符合条件的患者在完成疗程后停用所有抗病毒药物。临床数据显示,24%的Hibsago治疗组患者达到停药标准,停药6个月后19%患者仍维持病毒抑制且病毒蛋白不可检。
原文明确 FDA 批准 Hibsago 用于特定乙肝成人,并给出临床试验中停药后病毒控制的具体比例数据。
Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver—stopping all medication while the virus stays in check.
The U.S. Food and Drug Administration on Tuesday approved Hibsago (bepirovirsen) for certain adults with the long-term liver infection.
It's the first drug of its kind for hepatitis B. It works differently from existing antiviral pills by disrupting the genetic messages the virus needs to multiply.
Over time, chronic hepatitis B can scar the liver, a condition called cirrhosis, and raise the risk of liver cancer. About 1.7 million people in the United States have the infection, according to GSK, the drug's maker.
Standard antiviral treatment means a daily pill, typically for more than a year, according to the Hepatitis B Foundation.
"For many people living with chronic hepatitis B, treatment can mean taking antiviral medication for years to keep the virus suppressed," Dr. Wendy Carter, acting director of the FDA's Office of Infectious Diseases, said in a news release.
Hibsago isn't for everyone. It's approved for adults without cirrhosis who've been on antiviral medicine for at least six months, whose virus is suppressed and who have low levels of a viral protein called hepatitis B surface antigen.
Patients get Hibsago as a shot under the skin for up to six months, along with their usual medicine. After the first dose, they can choose to give themselves the injections, GSK said.
Once they've been off the shots for six months, those who meet certain health and lab requirements may be able to stop their regular medicine.
In two clinical trials, 24% of patients given Hibsago met those requirements, the FDA said. None of those given a placebo (an inactive treatment) did.
Six months after stopping all hepatitis B treatment, 19% of patients who got Hibsago were still keeping the virus in check. The viral protein also wasn't detectable in their blood.
GSK calls this result a "functional cure," meaning the immune system controls the infection without medicine.
Dr. Norah Terrault, chief of gastroenterology and hepatology at USC's Keck Medical Center in Los Angeles, called the approval "the start of a new era." Reaching a functional cure after a short course of treatment is "a long-standing goal for patients and physicians alike," she said in a GSK news release.
The drug carries serious risks. Its label includes a boxed warning, the FDA's strongest, for severe liver reactions and for low levels of platelets (blood cells that help stop bleeding), which can lead to life-threatening bleeding.
Patients need frequent blood work before and during treatment.
The Hepatitis B Foundation notes that there's still no complete cure for hepatitis B. It advises regular checkups with a liver specialist, usually every six months, whether or not people are being treated.
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: FDA approves hepatitis B shot that may let some patients stop all treatment (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-fda-hepatitis-shot-patients-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com